BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33155957)

  • 1. Prediction-Determining Outcomes and Their Predictors in Atrial Fibrillation Patients Receiving Multicomponent Antithrombotic Therapy in Real Clinical Practice.
    Krivosheeva EN; Panchenko EP; Kropacheva ES; Dobrovolsky AB; Titaeva EV; Mironov VM; Samko AN
    Kardiologiia; 2020 Sep; 60(8):33-45. PubMed ID: 33155957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thrombotic and hemorrhagic complications in atrial fibrillation patients, undergoing elective percutaneous coronary intervention].
    Krivosheeva EN; Kropacheva ES; Panchenko EP; Samko AN
    Ter Arkh; 2019 Sep; 91(9):38-46. PubMed ID: 32598813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticoagulation status and adherence in patients with atrial fibrillation hospitalized for ACS and the impact on 1-year prognosis: a multicenter cohort study].
    Zhu LY; Li Q; Yu LY; Liu Y; Chen YN; Wang Z; Zhang SY; Li J; Liu Y; Zhao YL; Xi Y; Pi L; Sun YH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Jul; 51(7):731-741. PubMed ID: 37460427
    [No Abstract]   [Full Text] [Related]  

  • 7. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.
    Olivier CB; Fan J; Askari M; Mahaffey KW; Heidenreich PA; Perino AC; Leef GC; Ho PM; Harrington RA; Turakhia MP
    Circ Cardiovasc Interv; 2019 Aug; 12(8):e007604. PubMed ID: 31416357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
    Sindet-Pedersen C; Lamberts M; Staerk L; Nissen Bonde A; Berger JS; Pallisgaard JL; Lock Hansen M; Torp-Pedersen C; Gislason GH; Olesen JB
    J Am Coll Cardiol; 2018 Oct; 72(15):1790-1800. PubMed ID: 30286922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
    Manzano-Fernández S; Pastor FJ; Marín F; Cambronero F; Caro C; Pascual-Figal DA; Garrido IP; Pinar E; Valdés M; Lip GYH
    Chest; 2008 Sep; 134(3):559-567. PubMed ID: 18641090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Kuno T; Ueyama H; Takagi H; Ando T; Numasawa Y; Briasoulis A; Fox J; Bangalore S
    Am J Cardiol; 2020 Feb; 125(4):521-527. PubMed ID: 31839147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Oral Anticoagulants Therapies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Mainka FF; Ferreira VL; Mendes AM; Marques GL; Fernandez-Llimos F; Tonin FS; Pontarolo R
    J Cardiovasc Pharmacol Ther; 2020 Sep; 25(5):399-408. PubMed ID: 32489116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention.
    Lyu SQ; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Yang YM
    Thromb Res; 2022 Jan; 209():16-22. PubMed ID: 34844044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
    Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
    Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry).
    Mennuni MG; Halperin JL; Bansilal S; Schoos MM; Theodoropoulos KN; Meelu OA; Sartori S; Giacoppo D; Bernelli C; Moreno PR; Krishnan P; Baber U; Lucarelli C; Dangas GD; Sharma SK; Kini AS; Tamburino C; Chieffo A; Colombo A; Presbitero P; Mehran R
    Am J Cardiol; 2015 Jul; 116(1):37-42. PubMed ID: 25956624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does HAS-BLED risk score underestimate the risk of bleeding in patients with triple antithrombotic therapy?
    Stojanovic M; Deljanin-Ilic M; Ilic S; Ilic B; Petrovic D
    Pol Merkur Lekarski; 2020 Oct; 48(287):361-364. PubMed ID: 33130800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
    Haller PM; Sulzgruber P; Kaufmann C; Geelhoed B; Tamargo J; Wassmann S; Schnabel RB; Westermann D; Huber K; Niessner A; Gremmel T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):226-236. PubMed ID: 31198930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.